Is NewMed Energy Limited Partnership (TASE:NWMD) Fairly Valued Following Its Bond Offering Call?
NewMed Energy - Limited Partnership (TASE:NWMD) has called a special meeting for 1 September 2026 to review a potential bond offering, putting its funding mix and balance sheet choices in sharper investor focus.
NewMed Energy Limited Partnership’s latest pullback, with a 7 day share price return down 3.34% and a year to date share price return down 10.31% to ₪16.52, sits against a much stronger backdrop, including a 1 year total shareholder return of 8.58% and a 5 year total shareholder return nearing 4x. This hints that investors may be reassessing near term funding risks rather than the longer term investment case.
Compare NewMed Energy - Limited Partnership’s funding rethink with other capital intensive plays by scanning a hand picked set of list of solid balance sheet and fundamentals (194 results) that may weather similar decisions differently.
With NewMed Energy - Limited Partnership pulling back while a bond issue is on the table, some investors may see a chance to step in now, while others might prefer to wait and see. Is the current valuation doing the heavy lifting already?
Most Popular Narrative: 7.7% Undervalued
The most followed narrative on NewMed Energy - Limited Partnership pegs fair value at ₪17.9, modestly above the last close of ₪16.52. This puts the debate squarely on whether the earnings story justifies that gap.
Heavy capital commitments to Leviathan phase two, Aphrodite and multiple midstream projects cluster large spending into the next few years. This can pressure free cash flow and limit flexibility if gas demand or realized prices soften, with potential knock on effects for earnings.
Investors may want to understand why this narrative still points to upside even with those spending pressures in view. The fair value call rests on a specific mix of revenue growth, margin progression and a future earnings multiple that is very different from where NewMed Energy - Limited Partnership trades today. The full story joins those moving parts into one valuation roadmap.
Result: Fair Value of ₪17.9 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the narrative can unravel if geopolitical disruption again interrupts Leviathan output or if Brent linked export pricing weakens and squeezes NewMed Energy Limited Partnership’s earnings quality.
Find out about the key risks to this NewMed Energy - Limited Partnership narrative.
Another View: What NewMed Energy’s P/E Is Saying
The SWS DCF model points to upside for NewMed Energy - Limited Partnership, yet the market is charging a P/E of 23.6x, which is much richer than both the Asian Oil and Gas industry at 12.1x and the peer average at 18.4x. That richer tag can mean investors are paying upfront for a lot of execution to go right. How comfortable are you with that gap?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around NewMed Energy - Limited Partnership is mixed, which creates a narrow window for you to review the data and decide quickly. To get a balanced view of both the concerns and the upside that other investors are tracking, start with these 2 key rewards and 3 important warning signs.
Looking for more NewMed Energy investment ideas?
If NewMed Energy - Limited Partnership has you rethinking your watchlist, do not stop with a single ticker. Broaden your options and pressure test your thesis using the Simply Wall St screener.
- Target resilience by reviewing a 99 resilient stocks with low risk scores that may help you focus on businesses with steadier risk profiles when markets turn choppy.
- Hunt for value by scanning a 618 high quality undiscovered gems that could highlight lesser known companies with strong fundamentals that the crowd might be overlooking.
- Strengthen your core holdings by using a 161 dividend fortresses that can point you toward income plays with higher yields that might complement NewMed Energy Limited Partnership in a diversified portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com